BG106548A - Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog - Google Patents

Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog

Info

Publication number
BG106548A
BG106548A BG106548A BG10654802A BG106548A BG 106548 A BG106548 A BG 106548A BG 106548 A BG106548 A BG 106548A BG 10654802 A BG10654802 A BG 10654802A BG 106548 A BG106548 A BG 106548A
Authority
BG
Bulgaria
Prior art keywords
receptor antagonist
synergistic combinations
structural analog
gaba
gaba analog
Prior art date
Application number
BG106548A
Other languages
Bulgarian (bg)
English (en)
Inventor
John Hughes
Lakhbir Singh
Original Assignee
Warner-Lambert Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company Llc filed Critical Warner-Lambert Company Llc
Publication of BG106548A publication Critical patent/BG106548A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Addiction (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BG106548A 1999-10-07 2002-03-22 Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog BG106548A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15827199P 1999-10-07 1999-10-07
PCT/EP2000/009858 WO2001024792A1 (en) 1999-10-07 2000-10-05 Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog

Publications (1)

Publication Number Publication Date
BG106548A true BG106548A (en) 2002-12-29

Family

ID=22567369

Family Applications (1)

Application Number Title Priority Date Filing Date
BG106548A BG106548A (en) 1999-10-07 2002-03-22 Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog

Country Status (38)

Country Link
EP (2) EP1221950B1 (de)
JP (2) JP2003510356A (de)
KR (1) KR20020060192A (de)
CN (1) CN1387434A (de)
AP (1) AP2002002501A0 (de)
AR (1) AR029646A1 (de)
AT (1) ATE269072T1 (de)
AU (2) AU7663300A (de)
BG (1) BG106548A (de)
BR (1) BR0014598A (de)
CA (1) CA2385930A1 (de)
CO (1) CO5280195A1 (de)
CR (1) CR6614A (de)
CZ (1) CZ20021116A3 (de)
DE (1) DE60011650T2 (de)
DK (1) DK1221950T3 (de)
EA (1) EA004266B1 (de)
EE (1) EE200200185A (de)
ES (1) ES2220542T3 (de)
GT (1) GT200000166A (de)
HR (1) HRP20020286A2 (de)
HU (1) HUP0203466A3 (de)
IL (1) IL148965A0 (de)
IS (1) IS6318A (de)
MA (1) MA26826A1 (de)
MX (1) MXPA02003484A (de)
NO (1) NO20021625D0 (de)
NZ (1) NZ517949A (de)
OA (1) OA12063A (de)
PA (1) PA8504301A1 (de)
PE (1) PE20010708A1 (de)
PL (1) PL357498A1 (de)
PT (1) PT1221950E (de)
SK (1) SK4542002A3 (de)
TR (1) TR200200913T2 (de)
UY (1) UY26376A1 (de)
WO (2) WO2001024792A1 (de)
ZA (1) ZA200202675B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001876A (en) 1996-07-24 1999-12-14 Warner-Lambert Company Isobutylgaba and its derivatives for the treatment of pain
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
CN1662231A (zh) * 2002-04-24 2005-08-31 柏树生物科学公司 包括应激相关障碍在内的功能性躯体障碍的预防与治疗
US20060039968A1 (en) * 2002-10-08 2006-02-23 Ramalingam Manikandan Gabapentin tablets and method for their preparation
WO2004084881A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING FUNCTIONAL BOWEL DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS
EP1492519B1 (de) * 2003-03-21 2006-11-15 Dynogen Pharmaceuticals, Inc. Verfahren zur behandlung von erkrankungen der unteren harnwege mit antimuskarinika und mit modulatoren der alpha-2-delta untereinheit des kalziumkanals
WO2004084880A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING PAIN USING SMOOTH MUSCLE MODULATORS AND α2δ SUBUNIT CALCIUM CHANNEL MODULATORS
EP1543831A1 (de) * 2003-12-18 2005-06-22 Pfizer GmbH Arzneimittelwerk Gödecke Zusammensetzung enthaltend Pregabalin
DE102007019071A1 (de) * 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin
MX2013000946A (es) 2010-07-30 2013-02-27 Toray Industries Agente terapeutico o agente profilactico para el dolor neuropatico.
EP3753410A3 (de) * 2010-09-28 2021-04-28 The Regents Of The University Of California Kombinationen enthaltend gaba agonisten zur behandlung von hyperglyzemie
ES3064256T3 (en) * 2019-03-26 2026-04-23 Orion Corp Pregabalin formulations and use thereof
WO2022234110A1 (en) * 2021-05-07 2022-11-10 Plus Vitech, S.L. Gamma-aminobutyric acid derivatives for use in cancer therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5025035A (en) * 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
US5792796A (en) * 1994-07-27 1998-08-11 Warner-Lambert Company Methods for treating anxiety and panic
US5510381A (en) * 1995-05-15 1996-04-23 Warner-Lambert Company Method of treatment of mania and bipolar disorder
DE69736390T2 (de) * 1996-10-07 2007-07-26 Merck Sharp & Dohme Ltd., Hoddesdon Zns-penetrierende nk-1 rezeptorantagonisten als antidepressivum und / oder anxiolytikum
WO1998024439A1 (en) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating severe anxiety disorders

Also Published As

Publication number Publication date
HRP20020286A2 (en) 2003-08-31
PT1221950E (pt) 2004-08-31
GT200000166A (es) 2002-03-30
CN1387434A (zh) 2002-12-25
CA2385930A1 (en) 2001-04-12
NO20021625L (no) 2002-04-05
CO5280195A1 (es) 2003-05-30
JP2003510356A (ja) 2003-03-18
WO2001024791A1 (en) 2001-04-12
JP2003510355A (ja) 2003-03-18
WO2001024792A9 (en) 2002-09-06
SK4542002A3 (en) 2003-09-11
AU7663300A (en) 2001-05-10
TR200200913T2 (tr) 2002-09-23
UY26376A1 (es) 2000-12-29
WO2001024792A1 (en) 2001-04-12
IL148965A0 (en) 2002-11-10
AR029646A1 (es) 2003-07-10
DE60011650T2 (de) 2005-07-14
PE20010708A1 (es) 2001-07-27
EE200200185A (et) 2003-04-15
ZA200202675B (en) 2003-04-15
AU1696201A (en) 2001-05-10
EP1221950B1 (de) 2004-06-16
EP1221950A1 (de) 2002-07-17
NZ517949A (en) 2003-08-29
EP1233766A1 (de) 2002-08-28
HUP0203466A3 (en) 2005-03-29
OA12063A (en) 2006-05-03
NO20021625D0 (no) 2002-04-05
AP2002002501A0 (en) 2002-06-30
IS6318A (is) 2002-03-21
MXPA02003484A (es) 2004-09-10
DK1221950T3 (da) 2004-09-20
ATE269072T1 (de) 2004-07-15
HUP0203466A2 (hu) 2003-02-28
CZ20021116A3 (cs) 2003-05-14
DE60011650D1 (de) 2004-07-22
EA004266B1 (ru) 2004-02-26
KR20020060192A (ko) 2002-07-16
CR6614A (es) 2003-12-04
PA8504301A1 (es) 2002-08-26
ES2220542T3 (es) 2004-12-16
BR0014598A (pt) 2002-06-11
MA26826A1 (fr) 2004-12-20
EA200200303A1 (ru) 2002-08-29
PL357498A1 (en) 2004-07-26

Similar Documents

Publication Publication Date Title
WO2001078698A3 (en) Use of ngf-antagonists for the prevention or treatment of chronic visceral pain
MY127980A (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
HUP0202319A3 (en) Use of mek inhibitors for the preparation of pharmaceutical compositions treating chronic pain
BG104727A (en) Pharmaceutical composition of topiramate
AU2003301190A1 (en) Administration of capsaicinoids
HK1040945A1 (zh) 包含曲马多物质和选择性cox-2抑制剂药物的组合物
ZA200110504B (en) Dietary or pharmaceutical compositions for use for the prevention or treatment of hyperoxaluria.
MXPA02003484A (es) Combinaciones sinteticas de un antagonista de receptor de nk1 y un analogo estructural de gaba.
MXPA06000705A (es) Combinacion de antagonista del receptor 2 de glutamato metabotropico (mglur2) e inhibidor de acetilcolinesterasa (ache) para tratar trastornos neurologicos agudos y/o cronicos.
NZ503233A (en) Synergistic analgesic combination of opioid analgesic and COX-2 inhibitor
IL101358A0 (en) Crystalline tiagabine hydrochloride monohydrate,its preparation and pharmaceutical compositions containing it
EP1032556A4 (de) Pharmazeutisch wirksame verbindungen und methoden zu ihrer anwendung
GB2274777B (en) Synergistic combination of compounds having an antagonist effect on nk1 and on nk2 receptors
IL145645A0 (en) N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists
EP0657167A3 (de) Verwendung von Oenothein B zur Herstellung eines Medikaments zur Behandlung der durch Hyperandrogenität bedingt Störungen, pharmaceutische Zusammensetzungen die Oenothein B enthalten und ein Verfahren zu ihrer Herstellung von Epilobium Parniflorum.
PL1656131T3 (pl) Zastosowanie betainy w leczeniu chromania przestankowego
BG105962A (en) Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders
CA2433785A1 (en) Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof
EE200100689A (et) IL6RIL6 kimääri kasutamine ravimi valmistamiseks,mis on ette nähtud neuroloogiliste haiguste ravimiseks, ning farmatseutiline kompositsioon
MY128529A (en) Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
EP0743068A3 (de) Zusammensetzung zur Hemmung von Knochenverlust welche Vanadylsulfat enthält
CY2499B1 (en) Use of nk-1 receptor antagonists for treating stress disorders.
HUP0203309A3 (en) Therapeutic combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino(2,3)-e indol-8-one and neuroleptics for treatment or prevention of phychotic disorders and pharmaceutical compositions containing them
GB9917290D0 (en) Pharmaceutical composition
IL156144A0 (en) Novel therapeutic use of a thienylcyclohexylamine derivative